Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;3(2):55-9.
doi: 10.1177/2042018812437181.

Efficacy and safety of ultra-long-acting insulin degludec

Ammar Wakil, Stephen L Atkin

Efficacy and safety of ultra-long-acting insulin degludec

Ammar Wakil et al. Ther Adv Endocrinol Metab. 2012 Apr.

Abstract

All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control. Insulin degludec is a new generation, ultra-long-acting basal insulin that forms soluble multihexamers at the injection site that slowly release insulin degludec monomers into the circulation giving a prolonged duration of action. Insulin degludec may provide a safe and convenient dosing option for patients who require some flexibility in adhering to an insulin regimen according to their lifestyle or circumstances. In this review we focus on the early phases of insulin degludec development.

Keywords: hypoglycaemia; insulin degludec; type 1 and type 2 diabetes; ultra-long-acting basal insulin.

PubMed Disclaimer

Conflict of interest statement

Professor Atkin has undertaken consultancy and received research money from most large pharmaceutical companies.

Figures

Figure 1.
Figure 1.
Insulin degludec structure; LysB29Nε-hexadecandioyl-γ-Glu desB30 human insulin.
See this image and copyright information in PMC

References

    1. Atkin S.L., Bain S., Gough S., Shestakova M., Raz I., Blonde L., et al. (2011) Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes. Diabetologia 54 (Suppl. 1): 542
    1. Birkeland K.I., Home P.D., Wendisch U., Ratner R.E., Johansen T., Endahl L.A., et al. (2011a) Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 34: 661–665 - PMC - PubMed
    1. Birkeland K.I., Raz I., Gough S., Atkin S.L., Shestakova M., Blonde L., et al. (2011b) Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes. Diabetologia 54 (Suppl. 1): S423 (1041-P).
    1. Donnelly L.A., Morris A.D., Evans J.M.M. for the DARTS/MEMO collaboration (2007) Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 100: 345–350 - PubMed
    1. Heise T., Hermanski L., Nosek L., Feldmann A., Rasmussen S., Stryhn T., et al. (2010) Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia 53 (Suppl. 1): S 387 - PubMed

LinkOut - more resources